Abstract
Malnutrition may result in a phosphate-deficient state owing to a chronically insufficient phosphate intake. Concomitant iron deficiency is common and often supplemented by the intravenous route. It is not widely recognized that some parenteral iron formulations can induce hypophosphatemia. Herein we report a case of a severe and symptomatic hypophosphatemia (0.18 mM, normal range 0.8–1.4 mM) associated with an inappropriately reduced tubular reabsorption of phosphate (33%, norm >95%) in a malnourished patient with anorexia/bulimia who received 2 × 500 mg iron carboxymaltose (FCM) intravenously. Despite intravenous and oral phosphate supplements, it required 2 months to achieve a normal serum phosphate level. Our case demonstrates that in a chronically malnourished and phosphate-deficient state intravenous FCM could potentially be dangerous. If this form of iron application cannot be avoided, phosphate supplementation before and after iron infusion as well as close monitoring of phosphate levels are needed.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment
Drug Safety Open Access 06 September 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout


References
Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT . Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009; 49: 2719–2728.
Hussain I, Bhoyroo J, Butcher A, Koch TA, He A, Bregman DB . Direct comparison of the safety and efficacy of ferric carboxymaltose versus iron dextran in patients with iron deficiency anemia. Anemia 2013; 2013: 169107.
Wolf M, Koch TA, Bregman DB . Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 2013; 28: 1793–1803.
Mani LY, Nseir G, Venetz JP, Pascual M . Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient. Transplantation 2010; 90: 804–805.
Subramanian R, Khardori R . Severe hypophosphatemia. Pathophysiologic implications, clinical presentations, and treatment. Medicine (Baltimore) 2000; 79: 1–8.
Vaucher P, Druais PL, Waldvogel S, Favrat B . Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: a randomized controlled trial. CMAJ 2012; 184: 1247–1254.
Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG . FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab 2009; 94: 2332–2337.
Hu MC, Shiizaki K, Kuro-o M, Moe OW . Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 2013; 75: 503–533.
Okada M, Imamura K, Iida M, Fuchigami T, Omae T . Hypophosphatemia induced by intravenous administration of saccharated iron oxide. Klin Wochenschr 1983; 61: 99–102.
Vadhan-Raj S, Strauss W, Ford D, Bernard K, Boccia R, Li J, Allen LF . Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron. Am J Hematol 2013; 89: 7–12.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Fierz, Y., Kenmeni, R., Gonthier, A. et al. Severe and prolonged hypophosphatemia after intravenous iron administration in a malnourished patient. Eur J Clin Nutr 68, 531–533 (2014). https://doi.org/10.1038/ejcn.2014.20
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ejcn.2014.20
This article is cited by
-
High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment
Drug Safety (2022)
-
High Risk of Hypophosphatemia in Patients with Previous Bariatric Surgery Receiving Ferric Carboxymaltose: A Prospective Cohort Study
Obesity Surgery (2020)
-
Ferric carboxymaltose
Reactions Weekly (2015)